PRESS RELEASE published on 04/07/2026 at 18:59, 1 month 1 day ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation de trésorerie et les revenus du programme d’Autorisation d’Accès Compassionnel (AAC) au 31 mars 2026. La trésorerie s'élevait à 3,2 millions d’euros avec des revenus de 2,6 millions d’euros Trésorerie Revenus Thérapie Génique GenSight Biologics Programme AAC
PRESS RELEASE published on 04/07/2026 at 18:59, 1 month 1 day ago Inside Information / News release on accounts, results GenSight Biologics reports cash position and revenue from early access program as of March 31, 2026. Operating cash burn, fundraising, and treatment proceeds highlighted Revenue Fundraising Cash Position GenSight Biologics Early Access Program
BRIEF published on 03/27/2026 at 07:35, 1 month 13 days ago GenSight Biologics Reports 2025 Financial Performance Financing Activities Cash Runway R&D Expenses Regulatory Milestones Financial Results 2025
BRIEF published on 03/27/2026 at 07:35, 1 month 13 days ago GenSight Biologics publie ses résultats financiers pour 2025 Activités De Financement Cash Runway Dépenses De R&D Résultats Financiers 2025 Étapes Réglementaires
PRESS RELEASE published on 03/27/2026 at 07:30, 1 month 13 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers consolidés estimés pour l'année 2025, marquée par des avancées réglementaires et une extension de l'horizon de trésorerie jusqu'en décembre 2026 Résultats Financiers 2025 GenSight Biologics Horizon De Trésorerie Avancées Réglementaires
PRESS RELEASE published on 03/27/2026 at 07:30, 1 month 13 days ago Inside Information / News release on accounts, results GenSight Biologics reported estimated full-year consolidated financial results for 2025, highlighting key regulatory milestones achieved and cash runway projection through December 2026 Financial Results Phase III Trial GenSight Biologics Cash Runway Regulatory Milestones
BRIEF published on 03/23/2026 at 09:53, 1 month 17 days ago Heights Capital Management dépasse 8% du capital de GENSIGHT BIOLOGICS Franchissement De Seuil Augmentation De Capital GenSight Biologics Capital Et Droits De Vote Heights Capital
BRIEF published on 03/23/2026 at 09:53, 1 month 17 days ago Heights Capital Management exceeds 8% of GENSIGHT BIOLOGICS' capital Capital Increase Threshold Crossing GenSight Biologics Capital And Voting Rights Heights Capital
PRESS RELEASE published on 03/23/2026 at 09:48, 1 month 17 days ago Franchissement de seuils Déclaration de franchissement de seuils par Heights Capital Management pour le compte de CVI Investments, Inc. concernant GENSIGHT BIOLOGICS S.A. publiée le 17 mars 2026 Déclaration Franchissement De Seuils Heights Capital Management Gensight Biologics S.A. CVI Investments
BRIEF published on 03/18/2026 at 10:20, 1 month 21 days ago GenSight Biologics finalizes its €1.7 million fundraising round Ordinary Shares Fundraising GenSight Biologics Gene Therapies Risk Factors
Published on 05/09/2026 at 01:30, 8 hours 38 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 10 hours 8 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 13 hours 30 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 14 hours 55 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 15 hours 6 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 14 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 14 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 15 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 15 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 15 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
